

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hitoshi Fujimiya et al.

Serial No.: 10/761885

Filed: January 21, 2004

FOR: COMPUTER SOFTWARE PROGRAM FOR
GRAPHICALLY DISPLAYING GENETIC LINKAGE
UNBALANCES, AND THE METHOD THEREOF

) Docket Number:

) Y03S013-US

) Group art Unit: Not known

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Information Disclosure Statement

Dear Sir:

Enclosed is a copy of the Information Disclosure Citation Form together with copies of the documents cited on that form. It is respectfully requested that the cited documents be considered and that the enclosed copy of the Information Disclosure Citation Form be initialed by the Examiner to indicate such consideration and a copy thereof returned to applicant(s).

Pursuant to 37 C.F.R. § 1.97(g) and (h), the submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed as an admission that the information cited in this statement is material to patentability.

The following is the translation of the underlined section in the Japanese reference (TOYO KITAMURA, Logic of Linkage Disequilibrium, Genetic Statistics in the post genome era, Oct. 10, 2001, Page 183-201, Kabushikigaisha Yodosha, Tokyo, Japan):

“D’ is considered to have optimal characteristics as a scale, because it depends only on the genetic distance between a marker and a disease gene locus.”

Pursuant to 37 C.F.R. § 1.97, this Information Disclosure Statement is being submitted under one of the following (as indicated by an "X" to the left of the appropriate paragraph):

X 37 C.F.R. §1.97(b).

____ 37 C.F.R. §1.97(c). If so, then enclosed with this Information Disclosure Statement is one of the following:

____ A certification pursuant to 37 C.F.R. §1.97(e) or

_____ A check for \$ _____ for the fee under 37 C.F.R. § 1.17(p).

_____ 37 C.F.R. § 1.97(d). If so, then enclosed with this Information Disclosure Statement are the following:

- (1) A certification pursuant to 37 C.F.R. §1.97(e)*;
- (2) A petition requesting consideration of the Information Disclosure Statement; and
- (3) A check for \$ _____ for the fee under 37 C.F.R. §1.17(p) for submission of the Information Disclosure Statement.

*37 C.F.R. 1.97 (d) includes the following Certification pursuant to 37 C.F.R. 1.97 (e):

_____ That each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to filing this statement.


_____ That no item of information contained in the information statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in 1.56(c) more than three months prior to filing of this statement.

If there are any additional charges, please charge Deposit Account No. 502270.


Should the Examiner have any questions or comments regarding the Information Disclosure Statement, the Examiner is invited to telephone the undersigned at the number listed below.

Date: May 7, 2004

Respectfully submitted,



Konomi Takeshita
Registration No. 38,333
Omori & Yaguchi USA, LLC
Agent for Applicant
Eight Penn Center, Suite 1901
1628 John F. Kennedy Blvd.
Philadelphia, PA 19103
Phone No. (215) 701-6349



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/761885
Filing Date	January 21, 2004
First Named Inventor	Hitoshi Fujimiya
Art Unit	Not Known
Examiner Name	Not Known
Attorney Docket Number	Y03S013-US

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JURG OTT, Analysis of Human Genetic Linkage, DATE?, Page 280-296, The Johns Hopkins University Press, Baltimore, US	
		TIANHUA NIU, ZHAOHUI S. QIN, XIPING XU, and JUN S. LIU, Bayesian Haplotype Inference for Multiple Linked Single-Nucleotide Polymorphisms, The American Journal of Human Genetics 70, Page 157-169, 2002, The University of Chicago Press, Chicago, IL	
		TOYO KITAMURA, Logic of Linkage Disequilibrium, Genetic Statistics in the post genome era, Oct. 10, 2001, Page 183-201, Kabushikigaisha Yodosha, Tokyo, Japan	
		KENNETH P. BURNHAM, and DAVID R. ANDERSON, Model Selection and Multimodel Inference, Page 60-97, 2002, Springer-Verlag New York, Inc., US	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.